We partner with leading pharmaceutical and biotech companies to help them unlock biological insights, tackle therapeutic challenges from new angles and develop novel drugs for a range of complex diseases.

Partnering - Collaborations Thumbnail.jpg


Work with us to enhance drug discovery and development

We enable our partners to leverage the benefits and insights of the Benevolent PlatformTM to drive innovation in drug discovery and generate novel treatments. Our versatile Platform can find targets for any disease and drug modality, and we can work with partners across every stage of the drug discovery process, including target identification, molecular design and precision medicine.

Our approach


Capabilities across the drug discovery process

Target identification

Access an ever-expanding data landscape to better understand complex underlying disease biology, and use our AI tools to find drug targets that have never been considered for a disease before.

Chemistry and molecular design

Determine the optimal drug design via our AI-augmented molecular design capabilities. We combine the power of computational chemistry and advanced AI to enable data-driven drug design.

Precision medicine and indication expansion

Identify key patient subgroups and biomarkers for targeted treatments using our AI-based approaches, increasing your probability of clinical success. We can also help identify the full expanse of disease indications relevant to your drug.

Contact us



Successful collaboration with AstraZeneca

We have consistently delivered results in our collaboration with AstraZeneca, who have so far selected a total of five targets to enter its portfolio – two in chronic kidney disease (CKD) and three in idiopathic pulmonary fibrosis (IPF).



Business partners

Academia and non-profit organisations


Work with us to discover novel insights and accelerate the development of your drug programmes using our versatile and proven drug discovery engine.



Discover the untapped potential of you r assets

BenevolentAI has partnered with 9xchange, a biopharma asset marketplace, to provide insights on potential asset repurposability and indication expansion. The partnership combines the 9xchange platform with one of BenevolentAI’s powerful AI workflows, used early in the COVID-19 pandemic to identify a now FDA-approved treatment. Through this partnership, asset owners can unlock trapped value and buyers can acquire assets with newly-identified indications that were unknown or not previously explored.

Our approach